U.S. market Closed. Opens in 11 hours 41 minutes

AVTE | Aerovate Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueN/AN/AN/AN/AN/A
Cost of Revenue96.00K68.00K15.00K1.00KN/A
Gross Profit-96.00K-68.00K-15.00K-1.00KN/A
Operating Expenses81.31M53.24M23.02M8.89M3.33M
Selling, General & Admin17.09M14.62M8.04M949.00K218.00K
Research & Development64.22M38.62M14.99M7.94M3.11M
Other Operating ExpensesN/A-79.00K-3.00K-647.00K1.00K
Operating Income-81.41M-53.24M-23.02M-8.89M-3.33M
Other Expenses / Income5.94M1.75M62.00K-722.00K1.00K
Before Tax Income-75.47M-51.49M-22.96M-9.61M-3.33M
Income Tax Expenses56.00K25.00K3.00K-572.00K1.00K
Net Income-75.52M-51.51M-22.96M-9.04M-3.33M
Interest ExpensesN/A-1.75M65.00K75.00KN/A
Basic Shares Outstanding26.33M24.47M24.41M24.41M24.41M
Diluted Shares Outstanding26.33M24.47M24.41M24.41M24.41M
EBITDA-81.31M-53.17M-23.01M-9.54M-3.33M
EBITDA Margin0.00%0.00%0.00%0.00%0.00%
EBIT-75.47M-53.24M-22.89M-9.54M-3.33M
EBIT Margin0.00%0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙